3 unknown, 2 completed, 1 active not recruiting. 6 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Unknown 3, Completed 2, Active not recruiting 1 |
| Phase 2 | 4 | Unknown 3, Completed 1 |
Follow B-Cell Prolymphocytic Leukemia: new trials by email Literature Review of B-Cell Prolymphocytic Leukemia trials Research Report on B-Cell Prolymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat - B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Completed | City of Hope Medical Center | 18 | 2018-04-27 | 2026-11-10 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Alexey Danilov, MD | 24 | 2017-07-17 | 2023-08-08 |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma PCAR-019 (anti-CD19 CAR-T cells) - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-10-01 | 2016-10-25 |
| PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma anti-CD19 CAR-NK cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-09-01 | 2016-12-06 |
| Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma PCAR-019 (anti-CD19 CAR-T cells) - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-07-01 | 2016-08-01 |
| Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 37 | 2014-10-14 | 2026-10-26 |
Leukemia, Lymphocytic, Chronic, B-Cell (6) · Leukemia, Prolymphocytic, B-Cell (6) · Lymphoma, Follicular (6) · Lymphoma, Mantle-Cell (6) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, B-Cell, Marginal Zone (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia, Hairy Cell (2) · Anemia (1) · Burkitt Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1)
Chronic Disease (6) · Disease Attributes (6) · Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Leukemia (6) · Leukemia, B-Cell (6) · Leukemia, Lymphoid (6) · Leukemia, Prolymphocytic (6) · Lymphatic Diseases (6) · Lymphoma (6) · Lymphoproliferative Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6)
Antigens, CD19 (3) · Sensitivity and Specificity (3) · Immunotherapy, Adoptive (2) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · Bendamustine Hydrochloride (1) · Cyclophosphamide (1) · Etoposide (1) · Pharmacogenomic Variants (1) · fludarabine phosphate (1) · ibrutinib (1) · obinutuzumab (1) · pevonedistat (1)
PersonGen BioTherapeutics (Suzhou) Co., Ltd. (3) · City of Hope Medical Center (2) · Alexey Danilov, MD (1)
China (3) · United States (3)
Alexey Danilov (1) · Craig Okada, M.D. (1) · Lin Yang, Ph.D. (1) · Tanya Siddiqi (1) · Xin Liu, Ph.D. (1) · Xingbing Wang, Ph.D. (1)
PMID 28054442, PMID 34196037, PMID 34492703, PMID 34515338, PMID 36631449
P30CA033572 (1), P30CA069533 (1)